Table of Contents Author Guidelines Submit a Manuscript
BioMed Research International
Volume 2015, Article ID 963569, 8 pages
http://dx.doi.org/10.1155/2015/963569
Clinical Study

High 15-F2t-Isoprostane Levels in Patients with a Previous History of Nonmelanoma Skin Cancer: The Effects of Supplementary Antioxidant Therapy

1Department of Nutrition, Federal University of Piauí (UFPI), Campus Universitário Ministro Petrônio Portella, 64049-550 Teresina, PI, Brazil
2School of Medical Sciences (FCM), University of Campinas (UNICAMP), 13083-887 Campinas, SP, Brazil
3Faculty of Pharmaceutical Sciences (FCF), University of Campinas (UNICAMP), 13083-859 Campinas, SP, Brazil
4Department of Biological and Health Science Center, Mackenzie Presbyterian University, 01302-907 São Paulo, SP, Brazil

Received 4 February 2015; Revised 10 May 2015; Accepted 14 May 2015

Academic Editor: Pierre Hainaut

Copyright © 2015 Betânia de Jesus e Silva de Almendra Freitas et al. This is an open access article distributed under the Creative Commons Attribution License, which permits unrestricted use, distribution, and reproduction in any medium, provided the original work is properly cited.

Abstract

Background. Phase I of this study was aimed at comparing the profiles of oxidative stress biomarkers in patients with history of nonmelanoma skin cancer (NMSC), previously treated with surgery, to the healthy subjects. Phase II aimed to evaluate the effects of supplementary antioxidant therapy on the levels of biomarkers in the case group. Materials and Methods. In Phase I, oxidative stress biomarkers were measured in blood samples obtained from 24 healthy subjects and 60 patients with history of NMSC previously treated with surgery. In Phase II, the 60 patients with history of NMSC were randomized into two subgroups, one receiving placebo () and the other () receiving vitamin C, vitamin E, and zinc supplementation for 8 weeks, followed by reevaluation of biomarkers. Results. In Phase I, patients with history of NMSC showed increased plasma concentrations of all biomarkers, but only 15--isoprostane was significantly higher than in the healthy subjects. Risk of NMSC increased by 4% for each additional 1 pg/mL increase in 15--isoprostane. In Phase II, supplementation did not significantly reduce levels of oxidative stress biomarkers. Conclusion. Patients with history of NMSC had significantly high 15--isoprostane plasma levels; supplementation did not result in significant reduction of oxidative stress biomarkers. This trial was registered with ClinicalTrials.gov (ID NCT02248584).